Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data.
Cancer registry
Germany
High-risk
Hormonal therapy
Prostate cancer
S3-guideline
Treatment
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
07 Jun 2022
07 Jun 2022
Historique:
received:
28
12
2021
accepted:
18
05
2022
entrez:
7
6
2022
pubmed:
8
6
2022
medline:
10
6
2022
Statut:
epublish
Résumé
This study assesses the use of hormonal therapy to treat high-risk localized prostate cancer (HRLPCa) cases diagnosed between 2005 and 2015. All N A total of 5361 HRLPCa cases were analyzed. Only 27.6% (95% confidence interval [CI]: 26.4-28.8%) of the HRLPCa cases received hormonal therapy in combination with radiotherapy. The use of combined hormonal therapy and radiotherapy varied from 19.8% in Saxony to 47.8% in Schleswig-Holstein. Application of hormonal therapy was higher for the locally advanced cases compared to the poorly differentiated cases (relative risk [RR] = 1.28; 95%CI: 1.19, 1.37). Older patients showed a slightly increased use of hormonal therapy (RR for a 10-year age increase = 1.09; 95%CI: 1.02, 1.16). Compared to PCa cases from the most affluent residential areas, cases from the least affluent (RR = 0.71; 95%CI: 0.55, 0.92) and medium (RR = 0.75; 95%CI: 0.58, 0.96) areas had decreased use of hormonal therapy. The introduction of the German S3-guideline did not make a marked difference in the uptake of both hormonal therapy and radiotherapy (RR = 1.02; 95%CI: 0.95, 1.09). This study found a low use of hormonal therapy among HRLPCa patients treated without surgery. The introduction of the German S3-guideline for prostate cancer treatment does not seem to have impacted hormonal therapy use.
Sections du résumé
BACKGROUND
BACKGROUND
This study assesses the use of hormonal therapy to treat high-risk localized prostate cancer (HRLPCa) cases diagnosed between 2005 and 2015.
METHODS
METHODS
All N
RESULTS
RESULTS
A total of 5361 HRLPCa cases were analyzed. Only 27.6% (95% confidence interval [CI]: 26.4-28.8%) of the HRLPCa cases received hormonal therapy in combination with radiotherapy. The use of combined hormonal therapy and radiotherapy varied from 19.8% in Saxony to 47.8% in Schleswig-Holstein. Application of hormonal therapy was higher for the locally advanced cases compared to the poorly differentiated cases (relative risk [RR] = 1.28; 95%CI: 1.19, 1.37). Older patients showed a slightly increased use of hormonal therapy (RR for a 10-year age increase = 1.09; 95%CI: 1.02, 1.16). Compared to PCa cases from the most affluent residential areas, cases from the least affluent (RR = 0.71; 95%CI: 0.55, 0.92) and medium (RR = 0.75; 95%CI: 0.58, 0.96) areas had decreased use of hormonal therapy. The introduction of the German S3-guideline did not make a marked difference in the uptake of both hormonal therapy and radiotherapy (RR = 1.02; 95%CI: 0.95, 1.09).
CONCLUSION
CONCLUSIONS
This study found a low use of hormonal therapy among HRLPCa patients treated without surgery. The introduction of the German S3-guideline for prostate cancer treatment does not seem to have impacted hormonal therapy use.
Identifiants
pubmed: 35672732
doi: 10.1186/s12885-022-09677-z
pii: 10.1186/s12885-022-09677-z
pmc: PMC9171996
doi:
Substances chimiques
Androgen Antagonists
0
Antineoplastic Agents, Hormonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
624Subventions
Organisme : Open Access Publishing by the German Research Foundation (DFG)
ID : NA
Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2009 Jun 20;27(18):2924-30
pubmed: 19433689
Adv Urol. 2012;2012:651061
pubmed: 22666241
Eur Urol. 2012 Jun;61(6):1096-106
pubmed: 22386839
Gesundheitswesen. 2020 Mar;82(S 01):S62-S71
pubmed: 31663107
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):8-15
pubmed: 22079721
Nat Rev Urol. 2018 Aug;15(8):498-510
pubmed: 29765147
BJU Int. 2020 Jun;125(6):810-816
pubmed: 30946523
Brachytherapy. 2019 May - Jun;18(3):322-331
pubmed: 30862436
BJU Int. 2017 Nov;120 Suppl 3:35-42
pubmed: 28749017
J Urol. 2008 Aug;180(2):451-9; discussion 460
pubmed: 18550100
World J Urol. 2016 May;34(5):665-72
pubmed: 26391484
Cancer Med. 2016 Sep;5(9):2649-56
pubmed: 27356493
Semin Oncol. 2017 Oct;44(5):347-357
pubmed: 29580436
BMC Med Inform Decis Mak. 2008 Sep 12;8:38
pubmed: 18789150
J Urol. 2009 Mar;181(3):956-62
pubmed: 19167731
Expert Rev Clin Pharmacol. 2018 Apr;11(4):425-438
pubmed: 29355037
Curr Opin Urol. 2013 Jul;23(4):349-54
pubmed: 23673512
Eur Urol Focus. 2021 Mar;7(2):332-339
pubmed: 31748122
JAMA Oncol. 2016 Sep 1;2(9):1236-8
pubmed: 27367418
J Natl Cancer Inst. 2006 Jun 21;98(12):839-45
pubmed: 16788157
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):61-66
pubmed: 27618951
BJU Int. 2010 Jan;105(1):49-56
pubmed: 20132102
Eur Urol. 2015 Jul;68(1):53-8
pubmed: 25813688
Nat Rev Clin Oncol. 2014 Jun;11(6):308-23
pubmed: 24840073
J Clin Oncol. 2008 May 20;26(15):2497-504
pubmed: 18413638
World J Urol. 2021 Jan;39(1):49-56
pubmed: 32253584
Lancet Oncol. 2010 Nov;11(11):1066-73
pubmed: 20933466
Lancet Oncol. 2015 Mar;16(3):320-7
pubmed: 25702876
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
J Clin Oncol. 2010 Mar 1;28(7):1117-23
pubmed: 20124165
Brachytherapy. 2016 Nov - Dec;15(6):695-700
pubmed: 27528590
Strahlenther Onkol. 2020 Feb;196(2):109-116
pubmed: 31784804
Eur Urol. 2016 Sep;70(3):429-35
pubmed: 26951945
Cancer. 2015 May 1;121(9):1414-21
pubmed: 25492369
Eur Urol Oncol. 2021 Apr;4(2):327-330
pubmed: 31411981
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90
pubmed: 15817329
Onkologie. 2010;33(7):396-400
pubmed: 20631488